Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / CD Molecules

Recombinant Human CD87/PLAUR/uPAR Protein, N-His

Catalog #:   YHF99101 Specific References (50) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: Q03405
Protein length: Leu23-Arg303
Overview

Catalog No.

YHF99101

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Leu23-Arg303

Predicted molecular weight

33.63 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

Q03405

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

MO3, Urokinase plasminogen activator surface receptor, uPAR, UPAR, CD87, PLAUR, U-PAR, Monocyte activation antigen Mo3

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Human CD87 / PLAUR / uPAR
References

Serum and urinary biomarkers in lupus nephritis: do suPAR and VEGF play a role?, PMID:40513062

Early neutrophil responses are potential biomarkers to predict severe COVID-19 in adults., PMID:40402813

The predictive value of suPAR for glomerular segmental sclerosis lesions in renal pathology., PMID:40364434

HIV-Tat upregulates the expression of senescence biomarkers in CD4+ T-cells., PMID:40342418

Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma., PMID:40317602

Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels and Long-Term Cardiovascular Outcomes in Survivors of Breast Cancer: A UK Biobank Study., PMID:40314383

Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study., PMID:40275185

Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer., PMID:40154091

The predictive value of postoperative soluble urokinase plasminogen activator receptor concentration for postoperative complications following valvular surgery., PMID:40088459

Soluble urokinase plasminogen activator receptor biomarker is not a predictor of mortality in high-risk hip fracture patients., PMID:40047907

Urokinase Plasminogen Activation System Modulation in Transformed Cell Lines., PMID:39859388

Inflammatory Markers and Measures of Cardiovascular Autonomic Neuropathy in Type 1 Diabetes., PMID:39727210

(Thio)chromenone derivatives exhibit anti-metastatic effects through selective inhibition of uPAR in cancer cell lines: discovery of an uPAR-targeting fluorescent probe., PMID:39668665

Role of plasma suPAR, sTNFR1, and sTNFR2 levels in risk stratification and outcome prediction of complicated acute kidney injury in elderly patients with coronavirus disease 2019., PMID:39561952

Significance of myeloperoxidase, pentraxin-3 and soluble urokinase plasminogen activator receptor determination in patients with moderate carotid artery stenosis., PMID:39508179

Transcriptomic analysis of profibrinolytic and fibrinolytic inhibitor genes in COVID-19 patients., PMID:39280271

Novel Biomarkers: Soluble Urokinase-Type Plasminogen Activator Receptor and Procalcitonin- and Histological Chorioamnionitis after Preterm Premature Rupture of Membranes., PMID:39227528

High-sensitive troponin T, suPAR and Beta-2-microglobulin changes in concentration during hemodialysis., PMID:39180468

A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge., PMID:38988231

CD87-targeted BiTE and CAR-T cells potently inhibit invasive nonfunctional pituitary adenomas., PMID:38987430

CHI3L1 on fibrinolytic system imbalance in chronic rhinosinusitis with nasal polyp., PMID:38975344

Prognostic Significance of Proteomics-Discovered Circulating Inflammatory Biomarkers in Patients With Pulmonary Arterial Hypertension., PMID:38874078

Associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders - A systematic review and meta-analysis., PMID:38857636

Endothelial-specific Enhancer as a Cis Element of PLAUR Regulation by TNF-alpha, IL-1beta, and VEGF., PMID:38715331

Association of suPAR, ST2, and galectin-3 with eGFR decline and mortality in patients with advanced heart failure with reduced ejection fraction., PMID:38715217

The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Early Indicator of Mortality in Pediatric Septic Shock., PMID:38708489

Association between serum levels of GDF-15, suPAR, PIVKA-II, sdLDL and clinical outcomes in hospitalized COVID-19 patients., PMID:38700782

Gene Association Study of the Urokinase Plasminogen Activator and Its Receptor Gene in Alzheimer's Disease., PMID:38669542

PLAU promotes cell proliferation and migration of head and neck cancer via STAT3 signaling pathway., PMID:38663475

Analysis of the Predictive Efficacy of Serum suPAR Combined with APN and IgE Test and the Relationship of Patients with CHF and Cardiac Function., PMID:38581326

Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response., PMID:38073374

Soluble urokinase plasminogen activator receptor, platelet aggregation, and carotid plaque thickness in diabetes: A cross-sectional analysis., PMID:38042098

Soluble Urokinase-Type Plasminogen Activator Receptor in Comatose Survivors After Out-of-Hospital Cardiac Arrest Treated with Targeted Temperature Management., PMID:37910781

Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis., PMID:37772350

Enhancing the invasive traits of breast cancers by CYP1B1 via regulation of p53 to promote uPAR expression., PMID:37661069

YY1 regulates the proliferation and invasion of triple-negative breast cancer via activating PLAUR., PMID:37552345

A Systemic and Local Comparison of Senescence in an Acute Anterior Cruciate Ligament Injury-A Pilot Case Series., PMID:37511942

Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis., PMID:37108340

PLAUR splicing pattern in hereditary angioedema patients' monocytes and macrophages., PMID:37086298

Plasma IL-6, TREM1, uPAR, and IL6/IL8 biomarkers increment further witnessing the chronic inflammation in type 2 diabetes., PMID:36848486

Urokinase plasminogen activator surface receptor restricts HIV-1 replication by blocking virion release from the cell membrane., PMID:36638209

The Association of PLAUR Genotype and Soluble suPAR Serum Level with COVID-19-Related Lung Damage Severity., PMID:36555850

Analysis of Circulating Tumor and Cancer Stem Cells Provides New Opportunities in Diagnosis and Treatment of Small Cell Lung Cancer., PMID:36142766

TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR., PMID:35864968

Comprehensive analysis of the importance of PLAUR in the progression and immune microenvironment of renal clear cell carcinoma., PMID:35675366

Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View., PMID:35493073

Identification of a Novel Theranostic Signature of Metabolic and Immune-Inflammatory Dysregulation in Myocardial Infarction, and the Potential Therapeutic Properties of Ovatodiolide, a Diterpenoid Derivative., PMID:35163208

Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome., PMID:35102231

Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients., PMID:35081737

Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19., PMID:34777349

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human CD87/PLAUR/uPAR Protein, N-His [YHF99101]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only